Open AccessInitial Clinical Experience with PCSK9 Inhibitors to Lower LDL Cholesterol in a University Lipid Clinic Setting
Author(s) -
Anthony P. Morise,
Jennifer Tennant,
Sari D. Holmes,
Danyel H. Tacker
Publication year - 2020
Language(s) - English
DOI - 10.21885/wvmj.2020.2
Subject(s) - pcsk9 , discontinuation , medicine , statin , evolocumab , familial hypercholesterolemia , gastroenterology , ldl cholesterol , cholesterol , kexin , lipoprotein , endocrinology , ldl receptor , apolipoprotein a1
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have demonstrated significant lowering of low-density lipoprotein (LDL) cholesterol in patients with atherosclerotic cardiovascular disease (ASCVD) and familial hypercholesterolemia (FH). We retrospectively reviewed data concerning use of PCSK9 inhibitors from patients in our university-based adult lipid clinic. Data collected included clinical pre-treatment variables and pre-and post-treatment non-fasting lipid profiles. Of 165 candidates, 163 were approved for PCSK9 inhibition (90% ASCVD and 10% FH). A majority of patients (72%) had statin intolerance. Treatment was provided and assessed in 141 patients. After three doses of medications, LDL cholesterol fell from 170 + 58 mg/dL to 76 + 45 mg/dL (55%, P 95% approval rate was obtained, and there was similar efficacy in LDL lowering to what has been previously reported irrespective of statin intolerance.